Tesamorelin
Muscle & Strength · Stabilized GHRH analog
Tier B-
What this is
Only FDA-approved GHRH analog for metabolic indication. Stanley 2014 NEJM showed liver fat reduction in HIV patients with NAFLD. Notable worsening of insulin sensitivity limits cohort applicability. Expensive at list price; becoming more common in off-label metabolic/longevity prescribing.
Mechanism
Synthetic trans-3-hexenoic acid-modified GHRH(1-44); FDA-approved (Egrifta) 2010 for HIV-associated lipodystrophy; reduces visceral adipose tissue
Dose & route
1.4 mg (Egrifta SV) or 2 mg (Egrifta) subQ daily
Citations
- https://pubmed.ncbi.nlm.nih.gov/25089071/
- https://pubmed.ncbi.nlm.nih.gov/25289682/
- https://pubmed.ncbi.nlm.nih.gov/20554977/
- https://pubmed.ncbi.nlm.nih.gov/28400207/
- https://pubmed.ncbi.nlm.nih.gov/39731401/
- https://pubmed.ncbi.nlm.nih.gov/36727674/
Links go to the source. If a link is dead or you want something re-checked, let me know.
This is an independent synthesis of published research by a non-clinician. Scores are opinions supported by citations, not prescriptions. See the full disclaimer and methodology for how this score was produced and what it does and doesn't mean.